However, although the essentiality of SWI/SNF for non-APL AML maintenance has been extensively demonstrated in vivo, to our knowledge few in vivo studies have explored the functional consequences of SWI/SNF alterations in other hematological malignancies [86]. This evidence concerns the gene SMARCA1 and acute promyelocytic leukemia.